TAF1L Antibody

What is TAF1L and what cellular functions does it regulate?

TAF1L is a TAF1 homologue that functions similarly with histone acetyltransferase activity. Both TAF1 and TAF1L are required for transcription initiation with RNA polymerase II, with TAF1 serving as a scaffold for binding TATA-box binding protein and TAFs to TFIID . Research has demonstrated TAF1L's involvement in regulating cell proliferation, migration, autophagy, and apoptosis, particularly in cancer cells . Unlike many other TFIID components, TAF1L is devoid of histone fold domains (HFDs) and participates in higher-order co-translational interactions within the transcription initiation complex .

What cancers have been associated with abnormal TAF1L expression?

Studies have identified TAF1L abnormalities across multiple cancer types:

• Oral squamous cell carcinoma (OSCC) - overexpression promotes cancer development

• Gastric cancer (GC) - higher expression correlates with worse prognosis

• Esophageal cancer - somatic mutations and overexpression

• Lung, colorectal, and urothelial cancers - deletions, point mutations, and abnormal expression

Bioinformatic analyses from TCGA datasets confirm significantly higher TAF1L expression in tumor tissues compared to normal tissues (p < 0.001) , suggesting a potential oncogenic role.

What experimental techniques commonly employ TAF1L antibodies?

TAF1L antibodies are utilized in several research techniques:

• Western blotting for protein expression quantification

• Immunohistochemical (IHC) staining for tissue localization and expression assessment

• Immunofluorescent (IF) staining for cellular localization studies

• Combined with single-molecule RNA fluorescence in situ hybridization (smFISH) for co-translational studies

• RNA immunoprecipitation (RIP) assays for studying protein-RNA interactions

Each technique requires specific optimization for TAF1L detection, as discussed in the advanced sections below.

How should I optimize immunohistochemistry protocols for TAF1L antibody?

Based on published protocols, follow these methodological steps for optimal TAF1L IHC:

• Prepare 4-micrometer-thick tissue sections from formalin-fixed paraffin-embedded tissues

• Incubate sections with primary rabbit anti-TAF1L antibody (1:250 dilution; e.g., 55170-1-AP, Proteintech) for 15 minutes

• Incubate with secondary antibody for 8 minutes

• Develop color with DAB for 10 minutes

For standardized interpretation, use the Remmele and Stegner scoring method:

• Score staining intensity: 0 (none), 1 (weak), 2 (moderate), 3 (intense), 4 (strongly intense)

• Score percentage of positive cells: 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%), 4 (76-100%)

• Calculate final score by multiplying intensity by percentage

• Define "low expression" as score <4 and "high expression" as score ≥4

This scoring system allows for consistent quantification across different studies and has been validated in gastric cancer research.

What is the relationship between TAF1L expression and clinical outcomes in cancer patients?

Research has identified significant correlations between TAF1L expression and clinical outcomes:

In gastric cancer:

Multivariate analysis confirms TAF1L as an independent prognostic factor:

TCGA validation data confirms that high TAF1L expression correlates with worse survival in microsatellite stable (MSS) groups (11.0 months vs. 35.0 months, p = 0.0046) and HER2-positive cases (24.0 months vs. 57.0 months, p = 0.0039) .

How does TAF1L interact with autophagy and apoptosis pathways in cancer cells?

TAF1L demonstrates a complex regulatory relationship with autophagy and apoptosis pathways:

• TAF1L knockdown via siRNA affects cell proliferation, migration, autophagy, and apoptosis in OSCC cells in vitro

• Importantly, TAF1L knockdown-induced apoptotic activation can be rescued by the autophagy activator Rapamycin

• This suggests TAF1L may facilitate cancer cell escape from apoptosis via autophagic activation

The mechanistic model indicates TAF1L acts as a pro-survival factor in cancer cells by promoting autophagy, which subsequently inhibits apoptotic pathways. This relationship has been confirmed in xenograft models, where TAF1L overexpression promotes OSCC tumor growth in vivo .

How can I design effective siRNA experiments to study TAF1L function?

For successful TAF1L knockdown experiments, consider these validated methodological approaches:

Effective siRNA sequences:

• TAF1L-siRNA#1: 5'-GCAUGAAGCUGUUAGCCAATT-3' and 5'-UUGGCUAACAGCUUCAUGCTT-3'

• TAF1L-siRNA#2: 5'-GGAAGACUCUGAUGUGGAUTT-3' and 5'-AUCCACAUCAGAGUCUUCCTT-3'

• TAF1L-siRNA#3: 5'-GGAUGGGAAACCUAAGCCUTT-3' and 5'-AGGCUUAGGUUUCCCAUCCTT-3'

• NC-siRNA (negative control): 5'-UCUCCGAACGUGUCACGUTT-3' and 5'-ACGUGACACGUUCGGAGAATT-3'

Experimental protocol:

• Transfect cells with siRNA for 48 hours

• Validate knockdown efficiency using Western blot with TAF1L antibody

• Conduct functional assays (proliferation, migration, apoptosis) at appropriate timepoints

• For rescue experiments, treat cells with 0.1 μM Rapamycin or diluent control for 16 hours following siRNA treatment

This approach allows for comprehensive assessment of TAF1L function while controlling for off-target effects through multiple siRNA sequences and appropriate controls.

What methods can detect TAF1L co-translational interactions with other proteins?

Research has employed sophisticated approaches to study TAF1L co-translational assembly:

• RNA immunoprecipitation (RIP) with microarray or qPCR analysis:

  • Performed on polysome extracts in the presence of cycloheximide to preserve translation complexes

  • TAF1L mRNA is enriched in IPs of several TFIID subunits (TAF2, TAF4, TAF5, TAF8, TAF10, TAF12, TBP)

• Combined single-molecule RNA fluorescence in situ hybridization (smFISH) with immunofluorescence (IF):

  • Uses N-terminal TAF1L antibody with TAF1L mRNA smFISH

  • Quantifies co-localization between TAF1L mRNA and various protein factors

  • Puromycin treatment serves as control by disrupting translation

  • Analysis revealed ~40% of TAF1L mRNAs co-localize with TAF7 spots, while lower percentages co-localize with other TFIID components

These techniques have revealed TAF1L nascent protein as a central hub in TFIID assembly, with multiple protein-RNA interactions occurring during translation .

How does TAF1L expression correlate with molecular subtypes in cancer?

TAF1L expression shows significant associations with several molecular markers and subtypes:

In gastric cancer, high TAF1L expression correlates with:

• HER2 positivity (p = 0.046)

• Deficient mismatch repair (dMMR) status (p = 0.011)

• Presence of signet-ring cells (p = 0.043)

• Lympho-vascular invasion (p = 0.038)

• Neural invasion (p = 0.005)

TCGA analysis shows TAF1L expression has significant positive correlations with DNA mismatch repair (MMR) protein genes (MLH1, MSH2, MSH6, PMS2) .

The clinical impact of TAF1L varies by molecular subgroup:

• In HER2-positive patients, high TAF1L is an independent prognostic risk factor (HR = 6.736, 95%CI = 1.373-33.032, p = 0.019)

• In pMMR patients, high TAF1L is an independent prognostic risk factor (HR = 2.291, 95%CI = 1.126-4.660, p = 0.022)

• In TAF1L-high patients, HER2 status remains an independent prognostic risk factor (HR = 4.832, 95%CI = 1.908-12.239, p = 0.001)

These correlations suggest potential therapeutic implications for targeting TAF1L in specific molecular subtypes of cancer.

How can I validate TAF1L antibody specificity for my experimental system?

To ensure antibody specificity, implement these validation approaches:

• Genetic manipulation controls:

  • Compare TAF1L antibody signal between wildtype cells and those with TAF1L knockdown (via siRNA) or overexpression

  • A specific antibody should show corresponding decreases or increases in signal intensity

• Western blot validation:

  • Confirm the antibody detects a band of the expected molecular weight (~120 kDa)

  • Verify reduced signal after siRNA treatment targeting TAF1L

  • Include positive control samples with known TAF1L expression

• Immunofluorescence specificity:

  • Perform parallel staining with secondary antibody alone to rule out non-specific binding

  • Use TAF1L siRNA-treated cells as negative controls

  • Verify co-localization with expected subcellular distribution patterns

• Cross-technique validation:

  • Compare expression patterns across multiple techniques (Western blot, IHC, IF)

  • Concordant patterns across techniques support antibody specificity

What are the key considerations for TAF1L quantification in heterogeneous tumor samples?

When analyzing TAF1L in heterogeneous tumor samples, consider these methodological aspects:

• Representative sampling:

  • Use multiple cores or sections from different regions of the tumor

  • Score both tumor center and invasive margins separately

  • Account for intratumoral heterogeneity in expression

• Standardized scoring:

  • Use the validated Remmele and Stegner scoring system for consistent quantification

  • Have two independent pathologists evaluate slides blindly

  • Implement third-party evaluation in cases of disagreement

• Molecular context analysis:

  • Correlate TAF1L expression with molecular subtypes (HER2, MMR status)

  • Consider cell-type specific expression in tumors with mixed histology

  • Account for signet-ring cell distribution when present (p = 0.043 correlation)

• Technical controls:

  • Include normal tissue controls in each staining batch

  • Use internal positive controls within each section when possible

  • Standardize image acquisition and analysis parameters

What are promising approaches for targeting TAF1L in cancer therapy?

Given TAF1L's role in cancer progression, several therapeutic strategies warrant investigation:

• Direct TAF1L inhibition:

  • Development of small molecule inhibitors targeting TAF1L histone acetyltransferase activity

  • Antisense oligonucleotides or siRNA-based approaches for targeted knockdown

  • Screening of compound libraries for TAF1L-protein interaction disruptors

• Targeting TAF1L-dependent pathways:

  • Combined inhibition of TAF1L and autophagy pathways, given their mechanistic connection

  • Exploiting synthetic lethality in TAF1L-high tumors

  • Stratifying patients for existing therapies based on TAF1L expression levels

• Biomarker applications:

  • Development of companion diagnostics using standardized TAF1L IHC

  • Monitoring TAF1L expression as a marker of treatment response

  • Using TAF1L status for patient stratification, particularly in HER2-positive cancers

The prognostic significance of TAF1L in specific molecular subtypes (HER2-positive, pMMR) suggests these patient populations may particularly benefit from TAF1L-targeted approaches .

How can TAF1L antibodies be applied in multi-parameter analysis of cancer samples?

Advanced applications of TAF1L antibodies in comprehensive cancer profiling include:

• Multiplex immunofluorescence:

  • Co-staining with TAF1L and markers of autophagy (LC3, Beclin-1)

  • Simultaneous detection of TAF1L with MMR proteins (MLH1, MSH2, MSH6, PMS2)

  • Integration with markers of proliferation, apoptosis, and immune infiltration

• Mass cytometry (CyTOF) approaches:

  • Metal-conjugated TAF1L antibodies for single-cell protein profiling

  • Integration with other cancer markers for comprehensive phenotyping

  • Correlation with clinical outcomes in large patient cohorts

• Spatial transcriptomics integration:

  • Combined analysis of TAF1L protein (by IHC) and mRNA (by smFISH)

  • Mapping TAF1L expression to specific tumor regions and microenvironments

  • Correlating with co-translational assembly partners identified through RIP studies

These approaches could provide deeper insights into TAF1L's role in the tumor microenvironment and its interaction with other cancer-related pathways.